Multiple outlets report that a landmark Australian study finds a large share of babies diagnosed with peanut allergy—about one third—can have the diagnosis removed within their first year of life. The findings indicate that some infants who test positive for peanut allergy may outgrow the condition or otherwise not have a persistent allergy, potentially reducing the long-term burden on children, families and health services.
New Scientist frames the result as clinically significant for early childhood allergy management and highlights the potential impact on healthcare systems. Medical Xpress, the Brisbane Times, The Age and the Sydney Morning Herald describe it as a “world-first” national program study that changes how Australia approaches infant food allergies. Across these reports, the core message is that the decades-long approach to diagnosing and managing peanut allergy in babies is being questioned, with more infants able to be cleared.
While all sources converge on the headline finding and the broad implications, their phrasing differs—some emphasise “grow out” of the allergy, while others focus on safely removing the diagnosis—reflecting different ways of describing the same underlying result.
